Continued Growth Seen for Carl Zeiss Meditec in First Half of Fiscal 2018/19

By



JENA, Germany—In the first half of fiscal year 2018/19 Carl Zeiss Meditec generated revenue of €667.2 million, representing an increase of 8.7 percent, or 6.8 percent adjusted for currency effects, versus the same period in the prior year. Earnings before interest and taxes (EBIT) increased significantly to €110.4 million, versus €88.2 million a year ago. The EBIT margin also increased, to 16.5 percent compared with 14.4 percent the prior year. “In the first half of 2018/19, we have continued on our growth path, with a strong contribution from new products and a high level of recurring revenue,” commented Dr. Ludwin Monz, president and CEO of Carl Zeiss Meditec AG.

The ophthalmic devices strategic business unit (SBU) increased its revenue by 9.2 percent in the first half of fiscal year 2018/19, or 7.4 percent adjusted for currency effects, to €490.7 million, compared with €449.3 million in the same period of the prior year. This revenue increase is mainly attributed to the unchanged high demand for laser vision correction solutions as well as products for cataract surgery.

Revenue in the company’s microsurgery SBU grew by 7.4 percent, or 5.2 percent adjusted for currency effects, to €176.5 million, compared with €164.4 million in the same period of the prior year. Sales of neurosurgical visualization systems for the treatment of tumors and vascular diseases remained strong, the company said.